United Kingdom

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

12 Jan 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Athersys reports Q3 loss per share $0.06
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Athersys Inc :Athersys reports third quarter 2017 results.Q3 loss per share $0.06.Q3 revenue $400,000 versus $300,000.Q3 revenue view $598,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.  Full Article

Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Athersys Inc ::Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan.Athersys - entered manufacturing services agreement with Nikon Cell for commercial production of its stem cell therapy in Japan for ischemic stroke.Athersys - technology transfer of stem cell production methods in preparation for potential commercialization in Japan after treasure clinical study.  Full Article

Athersys, FDA agree on design for ischemic stroke late-stage study
Wednesday, 28 Sep 2016 

Athersys Inc :Athersys receives FDA agreement under special protocol assessment for phase 3 study of multistem® treatment for ischemic stroke.  Full Article

Athersys qtrly loss per share $0.08
Tuesday, 9 Aug 2016 

Athersys Inc : Athersys reports second quarter 2016 results . Q2 revenue $600,000 versus $200,000 .Qtrly loss per share $0.08.  Full Article


Tiny stem cell companies close in on major heart disease goals

NEW YORK The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.